Pharmaceutical News

RSS

SkyePharma and GlaxoSmithKline reach agreement on payment of royalties for Paxil CR

SkyePharma has announced that it has entered into an amendment agreement with GlaxoSmithKline (GSK) in respect of Paxil CR. Under the terms of the amendment agreement, GSK will make a one-time payment of approximately $10 million.

28 Apr 2005

Australian clinical trial of potent new anticancer drug (CYT997)

Up to 30 patients with advanced incurable solid-tumours are to be involved in clinical trials of a potent new anticancer drug (CYT997), developed by Australian biotechnology company, Cytopia Limited.

27 Apr 2005

America's largest retail pharmacy is moving all over the counter single ingredient pseudoephedrine products behind the counter

Pseudoephedrine is the key precursor ingredient that can be converted into the illegal drug methamphetamine. After careful review of numerous state legislative proposals and law enforcement bulletins, CVS made the decision to move these products behind the counter in all of its 5,400 stores across 36 states over the next sixty days.

27 Apr 2005

Patients' lives at risk from substandard drugs say heart specialists

Global action is needed to counter the dangers of substandard life-saving drugs that are putting patients' lives and health at risk, according to heart specialists writing in the new (19 April) issue of Europe's leading cardiology journal, the European Heart Journal.

27 Apr 2005

Drug adverts are a haphazard approach to health promotion

As California State Assembly Bill 95 (Koretz, D-West Hollywood), designed to reign in drug marketing costs in California by requiring manufacturers of drugs for life-threatening chronic conditions to pay the state a rebate equal to the drug marketing cost, moves to the Assembly Appropriations Committee, AIDS Healthcare Foundation (AHF) -- cites a study and accompanying editorial published today in the Journal of American Medical Association (JAMA) that demonstrates the influence that Direct to Consumer Advertising (DTCA) has on physicians' prescribing decisions.

26 Apr 2005

EU calls for tougher warnings on antidepressants for kids

A committee of experts in Europe are calling for strong warnings to be placed on two classes of antidepressants, informing doctors and parents of the risk they could pose to children and adolescents.

25 Apr 2005

Wide variation in access to HIV medications across states

Twenty-one State AIDS Drug Assistance Programs (ADAPs) report limiting access to their programs in some way, including 11 with waiting lists, despite an increase in the national ADAP budget, according to the ninth annual National ADAP Monitoring Project Report released by the Kaiser Family Foundation and the National Alliance of State AIDS Directors (NASTAD).

23 Apr 2005

International internet drug ring shattered

Drug Enforcement Administration (DEA) Administrator Karen P. Tandy has announced the results of Operation “Cyber Chase”, a year-long Organized Crime Drug Enforcement Task Force (OCDETF) investigation that targeted international Internet pharmaceutical traffickers operating in the United States, India, Asia, Europe and the Caribbean. These e-traffickers distributed drugs world-wide using “rogue” Internet pharmacies.

23 Apr 2005

Pfizer recalls epilepsy medicine

Pfizer has voluntarily recalled one lot (40,000 bottles) of 100 mg capsules of its epilepsy medication, Neurontin, after a manufacturing mechanical failure resulted in some bottles containing empty or partially filled capsules.

23 Apr 2005

Sales of asthma therapies will jump from $8.4 billion in 2003 to $13.1 billion in 2013

Decision Resources, a research and advisory firms focusing on pharmaceutical and health care issues, forecasts that sales of asthma therapies in the United States, Japan, and Western Europe will jump from $8.4 billion in 2003 to $13.1 billion in 2013.

23 Apr 2005

Wyeth victorious in Philadelphia diet drug case

Wyeth has announced that the jury in the cases of Janice Kydd v. Wyeth and Kathy Huber v. Wyeth in the Philadelphia Court of Common Pleas found in favor of Wyeth. The verdict came at the close of the first (damages) phase of this bifurcated (two-phase) trial.

23 Apr 2005

Suicide link with epilepsy drugs examined

The U.S. Food and Drug Administration (FDA), is asking 14 drug manufacturers to check their data for any evidence that epilepsy drugs trigger suicidal thoughts or behaviour.

22 Apr 2005

Emergency contraceptive Plan B now available over the counter in Canada

The emergency contraceptive drug Plan B will now be available over the counter in all of Canada as Health Canada yesterday ended the prescription requirement for Paladin Labs Inc.'s contraceptive.

20 Apr 2005

Canada approves use of cannabis spray for MS sufferers

In a world first Canada has taken the lead in approving the use of a cannabis spray that relieves pain in multiple sclerosis sufferers.

20 Apr 2005

Fast Track designation for Terlipressin in type 1 hepatorenal syndrome

Protein Design Labs, Inc. and privately held Orphan Therapeutics, LLC today reported that the U.S. Food and Drug Administration (FDA) has granted Fast Track status to the development of terlipressin for the treatment of patients with type 1 hepatorenal syndrome (HRS).

20 Apr 2005

Halozyme Therapeutics receives FDA clearance for Cumulase

Halozyme Therapeutics has announced it has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for Cumulase for the treatment of oocytes to facilitate certain in vitro fertilization (IVF) procedures. The active pharmaceutical ingredient in Cumulase is the first and only recombinant human hyaluronidase approved in the United States for cumulus removal in the IVF process.

20 Apr 2005

New chemical reaction that could greatly accelerate pharmaceutical production

University of Toronto researchers have a developed a new chemical reaction that could greatly accelerate pharmaceutical production, while also cutting costs and toxic by-products.

19 Apr 2005

Patients' lives at risk from substandard drugs

19 Apr 2005

Cost-effectiveness of drugs may vary across borders

A study published in the journal Value in Health reviews variations in estimates of cost-effectiveness of pharmaceuticals from country to country. Data showed that the results seen in one country are not necessarily applicable in another and that decision makers need to interpret data from other countries very carefully.

19 Apr 2005

Pfizer voluntarily withdraws Bextra from New Zealand market

Pharmaceutical company Pfizer is voluntarily withdrawing the Cox-2 medicine Bextra from the New Zealand market following a request from Medsafe to suspend distribution and marketing, and will recall supplies of Bextra progressively from wholesale and pharmacy shelves over the next few days.

12 Apr 2005